1 completed, 1 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow CUDC-907: new trials by email Literature Review of CUDC-907 trials Research Report on CUDC-907
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer CUDC-907 - Thyroid Neoplasms, Poorly Differentiated and Undifferentiated Thyroid Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 7 | 2016-12-22 | 2018-12-21 |
| Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations CUDC-907 - Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations | Phase 2 | Completed | Curis, Inc. | 70 | 2016-07-01 | 2022-04-27 |
Thyroid Carcinoma, Anaplastic (1) · Thyroid Neoplasms (1)
Curis, Inc. (1) · National Cancer Institute (NCI) (1)
United States (2) · Spain (1)